PL3246016T3 - Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy - Google Patents

Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Info

Publication number
PL3246016T3
PL3246016T3 PL17176635.5T PL17176635T PL3246016T3 PL 3246016 T3 PL3246016 T3 PL 3246016T3 PL 17176635 T PL17176635 T PL 17176635T PL 3246016 T3 PL3246016 T3 PL 3246016T3
Authority
PL
Poland
Prior art keywords
composition containing
dry powder
powder composition
phosphodiesterase inhibitor
containing phosphodiesterase
Prior art date
Application number
PL17176635.5T
Other languages
English (en)
Inventor
Daniela Cocconi
Francesca Schiaretti
Roberto Bilzi
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3246016T3 publication Critical patent/PL3246016T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17176635.5T 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy PL3246016T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03

Publications (1)

Publication Number Publication Date
PL3246016T3 true PL3246016T3 (pl) 2025-06-16

Family

ID=43262631

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17176635.5T PL3246016T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy
PL11741172T PL2600830T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11741172T PL2600830T3 (pl) 2010-08-03 2011-07-27 Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy

Country Status (39)

Country Link
US (2) US9132121B2 (pl)
EP (2) EP3246016B1 (pl)
JP (1) JP6004233B2 (pl)
KR (1) KR101805958B1 (pl)
CN (2) CN103052379A (pl)
AR (1) AR082443A1 (pl)
AU (1) AU2011287711B2 (pl)
BR (1) BR112013002506A2 (pl)
CA (1) CA2807256C (pl)
CL (1) CL2013000293A1 (pl)
CO (1) CO6690744A2 (pl)
CY (1) CY1120605T1 (pl)
DK (2) DK3246016T3 (pl)
EA (2) EA024922B1 (pl)
ES (2) ES2664175T3 (pl)
FI (1) FI3246016T3 (pl)
GE (1) GEP20156343B (pl)
HR (2) HRP20250711T1 (pl)
HU (2) HUE037620T2 (pl)
IL (1) IL224517B (pl)
LT (2) LT3246016T (pl)
MA (1) MA34449B1 (pl)
ME (1) ME03022B (pl)
MX (1) MX346424B (pl)
MY (1) MY179703A (pl)
NO (1) NO2600830T3 (pl)
NZ (1) NZ606548A (pl)
PE (2) PE20130601A1 (pl)
PH (1) PH12013500235A1 (pl)
PL (2) PL3246016T3 (pl)
PT (2) PT2600830T (pl)
RS (2) RS66876B1 (pl)
SG (1) SG187258A1 (pl)
SI (2) SI2600830T1 (pl)
SM (1) SMT202500256T1 (pl)
TR (1) TR201807012T4 (pl)
UA (1) UA112296C2 (pl)
WO (1) WO2012016889A2 (pl)
ZA (1) ZA201300870B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
RU2626956C2 (ru) 2011-06-06 2017-08-02 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
MX370104B (es) * 2013-10-22 2019-12-02 Chiesi Farm Spa Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
TR201818680T4 (tr) * 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
IL316500A (en) 2022-04-27 2024-12-01 Chiesi Farm Spa Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
CA3268243A1 (en) * 2022-09-22 2024-03-28 Chiesi Farm Spa CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
CN119923250A (zh) * 2022-09-22 2025-05-02 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器
CN119923251A (zh) * 2022-09-22 2025-05-02 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
WO1999014604A1 (de) 1997-09-16 1999-03-25 Trench Switzerland Ag Spannungsteiler
EP1158958B1 (en) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
KR100956703B1 (ko) * 2005-06-06 2010-05-06 에프. 호프만-라 로슈 아게 간 카르니틴 팔미토일 전이효소(l-cpt1) 저해제로서유용한 설폰아마이드 유도체
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
RU2626956C2 (ru) 2011-06-06 2017-08-02 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
MX370104B (es) 2013-10-22 2019-12-02 Chiesi Farm Spa Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).

Also Published As

Publication number Publication date
RS66876B1 (sr) 2025-07-31
CL2013000293A1 (es) 2013-05-03
KR20130094784A (ko) 2013-08-26
US20120031403A1 (en) 2012-02-09
LT3246016T (lt) 2025-05-26
US9132121B2 (en) 2015-09-15
AR082443A1 (es) 2012-12-05
BR112013002506A2 (pt) 2016-05-31
NO2600830T3 (pl) 2018-07-21
PE20130601A1 (es) 2013-05-30
AU2011287711B2 (en) 2016-10-27
EP2600830A2 (en) 2013-06-12
EA024922B1 (ru) 2016-11-30
MY179703A (en) 2020-11-11
WO2012016889A2 (en) 2012-02-09
SI2600830T1 (en) 2018-05-31
PT2600830T (pt) 2018-04-02
LT2600830T (lt) 2018-04-10
HRP20250711T1 (hr) 2025-08-15
PE20171256A1 (es) 2017-08-28
SMT202500256T1 (it) 2025-09-12
CA2807256A1 (en) 2012-02-09
JP2013532705A (ja) 2013-08-19
HRP20180717T1 (hr) 2018-07-13
ES2664175T3 (es) 2018-04-18
SI3246016T1 (sl) 2025-06-30
CA2807256C (en) 2018-08-28
AU2011287711A1 (en) 2013-02-21
HUE071256T2 (hu) 2025-08-28
FI3246016T3 (fi) 2025-07-08
PT3246016T (pt) 2025-06-25
CN103052379A (zh) 2013-04-17
DK2600830T3 (en) 2018-03-12
EA201390049A1 (ru) 2013-05-30
SG187258A1 (en) 2013-03-28
GEP20156343B (en) 2015-08-10
EP3246016A1 (en) 2017-11-22
DK3246016T3 (da) 2025-05-19
MA34449B1 (fr) 2013-08-01
ME03022B (me) 2018-10-20
HUE037620T2 (hu) 2018-09-28
RS57061B1 (sr) 2018-06-29
CY1120605T1 (el) 2019-12-11
MX2013001172A (es) 2013-03-07
EA027692B1 (ru) 2017-08-31
ZA201300870B (en) 2014-04-30
IL224517B (en) 2018-04-30
EA201690541A1 (ru) 2016-07-29
NZ606548A (en) 2015-02-27
PH12013500235A1 (en) 2016-05-25
US9308200B2 (en) 2016-04-12
UA112296C2 (uk) 2016-08-25
KR101805958B1 (ko) 2017-12-07
CN106890165A (zh) 2017-06-27
PL2600830T3 (pl) 2018-08-31
MX346424B (es) 2017-03-21
JP6004233B2 (ja) 2016-10-05
EP2600830B1 (en) 2018-02-21
WO2012016889A3 (en) 2012-04-19
US20150342936A1 (en) 2015-12-03
TR201807012T4 (tr) 2018-06-21
EP3246016B1 (en) 2025-04-09
ES3033142T3 (en) 2025-07-31
CO6690744A2 (es) 2013-06-17

Similar Documents

Publication Publication Date Title
PL3246016T3 (pl) Kompozycja suchego proszku zawierająca inhibitor fosfodiesterazy
PT2593094T (pt) Composição aquosa contendo bromexina
SMT201500263B (it) Composizioni solide
BR112012031667A2 (pt) composição
EP2558297A4 (en) Powder overlay
DK2640893T4 (da) Sammensætninger
LT3246021T (lt) Apiksabano kompozicijos
IL232113A0 (en) Arginase inhibitor compounds, preparations containing them and their uses
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
LT3158991T (lt) Bendamustino kompozicijos
BR112012032683A2 (pt) composição
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
EP2559720A4 (en) NETWORKED COMPOSITION
BR112012032980A2 (pt) composição
EP2628769A4 (en) FILM FORMING COMPOSITION
FR2935592B1 (fr) Poudrier
EP2635269A4 (en) COMBINATION COMPOSITION
DK2628396T3 (da) Pulverblanding
FR2957252B1 (fr) Composition cosmetique
EP2623092A4 (en) COSMETIC COMPOSITION
DK2553004T3 (da) Sammensatte materialer
EP2548928A4 (en) PIGMENT COMPOSITION